Oral Pill Dabogratinib Shows 79% Response Rate in Intermediate-Risk Bladder Cancer Trial

The critical juncture in treating low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) arrives immediately after the initial tumor is surgically removed. At this specific step, patients and their urologists must make a choice that dictates the disease's trajectory: undergo repeated, uncomfortable catheterizations to deliver preventive medication directly into the bladder, or simply watch and wait. "As a community-based urologist, one of the greatest challenges isn't identifying patients who could benefit from therapy—it's that many choose surveillance because the burden of repeated catheterization and intravesical treatments outweighs the perceived benefit," said Mark Silva, MD, of Greater Boston Urology. Because the standard treatments are so physically burdensome, approximately 70% of patients opt for surveillance, effectively leaving the door open for the cancer to return.[2]

That decision point is exactly why new data from the Phase 2 SURF302 trial is generating substantial optimism among oncologists and urologists. Tyra Biosciences has reported that an investigational oral pill, dabogratinib, produced a 79% overall response rate in patients taking a 60-milligram daily dose. For the patients navigating this disease, the clinical translation is straightforward: a once-daily tablet taken at home could replace the need for hospital-based catheter procedures while actively suppressing the cancer's return. The prospect of an oral alternative fundamentally alters the risk-benefit calculation for those who would otherwise choose to wait for a recurrence.[1][5]

The SURF302 trial focused exclusively on patients whose tumors carry an alteration in the FGFR3 gene. This specific genetic mutation is present in a significant majority of intermediate-risk bladder cancer cases, acting as an engine that drives the cells to grow and divide too quickly. Dabogratinib is a precision medicine designed to selectively inhibit this exact protein. By targeting FGFR3 directly, the drug aims to halt the cellular signals that fuel tumor growth while sparing the surrounding healthy tissue that relies on other, similar proteins to function normally, thereby avoiding the widespread toxicity seen with older drugs.[6][7]

The initial efficacy data, drawn from 14 evaluable patients receiving the 60-milligram dose, demonstrated that the targeted approach is yielding tangible results. Beyond the 79% overall response rate, 64% of the patients achieved a complete response—meaning no detectable signs of cancer remained—as their best overall outcome. The trial also tested a lower 50-milligram dose in 12 patients, which produced a 67% overall response rate and a 33% complete response rate. This established a clear dose-response relationship that strongly favors the higher 60-milligram target for maximizing tumor suppression without compromising patient safety.[3][4]

The results were even more pronounced in a specific subset of patients who entered the trial with only a single marker lesion. This minimal disease state closely mirrors the "adjuvant" setting in real-world clinics, where doctors aim to clean up microscopic, invisible disease immediately after a tumor is resected. In that single-lesion subgroup, all eight patients (100%) responded to the 60-milligram dose, with 75% achieving a complete response. For urologists, this suggests that the drug is particularly highly effective when the overall tumor burden is low, exactly when adjuvant therapy is meant to be deployed.[2][3]

Durability—the ability of the drug to keep the cancer away over time—also showed early promise in the SURF302 data. According to the trial investigators, all patients who achieved a complete response at the three-month mark and reached their six-month assessment remained entirely cancer-free. Furthermore, the very first patient enrolled in the study has maintained a complete response at 12 months and continues to take the medication at 14 months. These sustained responses suggest that chronic, daily dosing can successfully maintain the disease's suppression over the long term without the cancer developing rapid resistance.[3]

Safety and tolerability are the other half of the equation, particularly for a medication intended for long-term, daily use in patients who currently feel well. At the 60-milligram dose, the safety profile strongly supported the case for chronic administration. There were no treatment-related discontinuations and no dose reductions required among the patients taking the higher dose. While 14% of patients at 60 milligrams experienced Grade 3, or severe, treatment-emergent adverse events, there were no Grade 4 or 5 events reported, indicating that the drug's side effects are generally manageable in an outpatient setting.[3][5]

Crucially, researchers noted an absence of the specific, quality-of-life-destroying toxicities that typically plague older, less selective FGFR inhibitors. There were no cases of clinically significant hyperphosphatemia—dangerously elevated phosphate levels in the blood—nor were there instances of nail toxicity or ocular toxicity. The most common side effects observed at the 60-milligram dose were fatigue, dry eye, and diarrhea. Investigators noted that the gastrointestinal side effects were generally mild, transient, and easily managed, allowing patients to maintain their daily routines without significant interruption.[3][5]

It is important to frame these results with the appropriate clinical caution. The data, reflecting an August 2026 cutoff, stems from a small, early-stage cohort of just 26 total evaluable patients across the two dose levels. As the trial continues to enroll up to 90 participants and the current patients are followed for longer periods, the response rates and safety signals could shift. The manufacturer has explicitly noted that all responses remain subject to change with continued treatment and extended follow-up, a standard caveat for Phase 2 oncology trials.[3][6]

Despite the small sample size, the 60-milligram dose has now been firmly identified as the target for a planned Phase 3 registrational study. If those larger, definitive trials confirm these initial signals, dabogratinib could become the first oral therapy approved specifically for this bladder cancer population. For patients, that would fundamentally shift the post-surgery conversation from a difficult choice between invasive catheters and anxious waiting, to a simple, daily pill that actively protects their health and preserves their quality of life.[2][5]